Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

Key Points

• To evaluate the cost-effectiveness of pembrolizumab plus chemotherapy compared to cemiplimab plus chemotherapy for first-line treatment of metastatic non-small cell lung cancer.
• Used matching-adjusted indirect comparison (MAIC) to analyze data from existing trials.
• Assessed overall survival and progression-free survival outcomes.
• Evaluated cost implications from a US payer perspective.
• Pembrolizumab plus chemotherapy resulted in improved overall survival compared to cemiplimab plus chemotherapy.
• Progression-free survival was also better with pembrolizumab plus chemotherapy.
• The treatment showed modest incremental costs, indicating economic viability.